Iovance gains after Q2 revenue beat

** Iovance Biotherapeutics IOVA.O shares gain 15.2% to $5 premarket

** Co posts Q2 revenue of $99.3 million beating estimates of $87.83 million, as per LSEG data

** CEO Frederick Vogt says based on Q2 performance and strong demand trends, co is reviewing previously issued 2026 revenue forecast of $350 million to $370 million and will provide an update during Q3

** Quarterly net loss per share narrowed to 11 cents from loss of 33 cents a year ago

** As of June 30, 2026, Iovance's cash position was ~$304 million and current cash is expected to fund operations into H2 2028

** Up to last close, stock up ~59% YTD